These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 27147206)

  • 1. FDA approves biosimilar version of infliximab.
    Traynor K
    Am J Health Syst Pharm; 2016 May; 73(10):604-6. PubMed ID: 27147206
    [No Abstract]   [Full Text] [Related]  

  • 2. Biosimilar infliximab: an expert view.
    Genazzani A; Altomare G; Balato N; Cusano F; De Pità O; Loconsole F; Micali G; Piaserico S; Girolomoni G
    G Ital Dermatol Venereol; 2015 Aug; 150(4):449-59. PubMed ID: 25747260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale, Opportunities, and Reality of Biosimilar Medications.
    Lyman GH; Zon R; Harvey RD; Schilsky RL
    N Engl J Med; 2018 May; 378(21):2036-2044. PubMed ID: 29791832
    [No Abstract]   [Full Text] [Related]  

  • 4. Brief Report: Utilization of the First Biosimilar Infliximab Since Its Approval in South Korea.
    Kim SC; Choi NK; Lee J; Kwon KE; Eddings W; Sung YK; Ji Song H; Kesselheim AS; Solomon DH
    Arthritis Rheumatol; 2016 May; 68(5):1076-9. PubMed ID: 26662931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infliximab Biosimilars in the Age of Personalized Medicine.
    Kang J; Pisupati K; Benet A; Ruotolo BT; Schwendeman SP; Schwendeman A
    Trends Biotechnol; 2018 Oct; 36(10):987-992. PubMed ID: 29861288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Scientific rationale behind the development and approval of biosimilar infliximab (CT-P13) in Europe.
    Müller-Ladner U; Hong S; Oh C; Taylor P
    Expert Rev Clin Immunol; 2015; 11 Suppl 1():S5-14. PubMed ID: 26395832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CT-P13 in the treatment of rheumatoid arthritis.
    Yoo DH
    Expert Rev Clin Immunol; 2017 Jul; 13(7):653-666. PubMed ID: 28571501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utilization and Treatment Costs of Tumor Necrosis Factor Inhibitors After the Introduction of Biosimilar Infliximab in the United States.
    Kim SC; Sarpatwari A; Landon JE; Desai RJ
    Arthritis Rheumatol; 2020 Jun; 72(6):1036-1038. PubMed ID: 31943866
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmaceuticals and medical devices: FDA oversight. Issue brief.
    Thomson Reuters/West
    Issue Brief Health Policy Track Serv; 2011 Jan; ():1-39. PubMed ID: 21374841
    [No Abstract]   [Full Text] [Related]  

  • 10. Therapy: Facing up to biosimilar agents--the ACR position.
    Scheinberg M
    Nat Rev Rheumatol; 2015 Jun; 11(6):322-4. PubMed ID: 25907701
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical and scientific aspects related to biosimilars in inflammatory bowel diseases (IBD): position document of the Belgian IBD Research & Development Group (BIRD).
    Vermeire S; Louis E; Dewit O; Franchimont D; Moreels T; Ferrante M; Rahier JF; Van Hootegem P; De Vos M; Mana F; Baert F;
    Acta Gastroenterol Belg; 2015; 78(1):26-9. PubMed ID: 26118575
    [No Abstract]   [Full Text] [Related]  

  • 12. FDA approves first biosimilar, zarxio.
    Colwell J
    Cancer Discov; 2015 May; 5(5):460. PubMed ID: 25790983
    [No Abstract]   [Full Text] [Related]  

  • 13. The US Biosimilar Market: Stunted Growth and Possible Reforms.
    Sarpatwari A; Barenie R; Curfman G; Darrow JJ; Kesselheim AS
    Clin Pharmacol Ther; 2019 Jan; 105(1):92-100. PubMed ID: 30415479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDA targets unapproved drugs.
    Young D
    Am J Health Syst Pharm; 2007 Feb; 64(4):347-8. PubMed ID: 17299170
    [No Abstract]   [Full Text] [Related]  

  • 15. The nocebo effect challenges the non-medical infliximab switch in practice.
    Boone NW; Liu L; Romberg-Camps MJ; Duijsens L; Houwen C; van der Kuy PHM; Janknegt R; Peeters R; Landewé RBM; Winkens B; van Bodegraven AA
    Eur J Clin Pharmacol; 2018 May; 74(5):655-661. PubMed ID: 29368188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases.
    Braun J; Kudrin A
    Immunotherapy; 2015; 7(2):73-87. PubMed ID: 25713985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tort claims and federal regulation of medical devices vs pharmaceuticals.
    Green M
    JAMA; 2009 Sep; 302(11):1169; author reply 1169-70. PubMed ID: 19755694
    [No Abstract]   [Full Text] [Related]  

  • 18. Biosimilars in the United States: Emerging Issues in Litigation.
    Wong AY; Rumore MM; Chan AW
    BioDrugs; 2017 Jun; 31(3):189-205. PubMed ID: 28424972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching to biosimilar infliximab (CT-P13): Evidence of clinical safety, effectiveness and impact on public health.
    Braun J; Kudrin A
    Biologicals; 2016 Jul; 44(4):257-266. PubMed ID: 27117857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biosimilars in IBD: from theory to practice.
    Danese S; Bonovas S; Peyrin-Biroulet L
    Nat Rev Gastroenterol Hepatol; 2017 Jan; 14(1):22-31. PubMed ID: 27729659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.